Search results
Based on the currently available evidence and antibiotic stewardship principles, the committee recommends restrictive use of antibacterial drugs in patients with community-acquired respiratory infection and proven or high likelihood of COVID-19.
- Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin ...
Moxifloxacin. Since the beginning of the COVID-19 pandemic,...
- Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin ...
11 sie 2023 · There is an opportunity to improve antibiotic prescribing guidelines in terms of both quality and incorporation of antimicrobial stewardship principles. These findings can help guideline developers better address antibiotic stewardship in future recommendations beyond COVID-19.
11 lis 2020 · Being able to reliably and expeditiously identify the risk of disease and progression, in which infected patients with COVID-19 will develop severe pneumonia and disease, could help clinicians in risk stratifying patients and ensuring appropriate care and resources are available.
Moxifloxacin. Since the beginning of the COVID-19 pandemic, researchers have focused on repurposing of existing antibiotics, antivirals and anti-inflammatory drugs to find an effective therapy. Fluoroquinolones are broad spectrum synthetic antimicrobial agents, being chemical derivatives of quinoline, the prodrom ….
To evaluate the prevalence of antibiotic use, patients were defined as receiving empiric antibiotic treatment for COVID-19 if antibiotics were started within 3 days of COVID-19 diagnosis and within 3 days of the first chest radiograph of pneumonia in those with COVID-19 pneumonia.
23 gru 2020 · Effective and safe therapies are desperately needed to treat COVID-19 as well as other betacoronavirus infections that are likely to emerge in the future. A massive worldwide effort to identify antivirals has, thus far, resulted in the FDA approval of remdesivir to treat COVID-19 [7, 8].
1 paź 2020 · Considering the potential antiviral activity of respiratory fluoroquinolones against SARS-CoV-2, along with their immunomodulatory properties, their favorable pharmacokinetics and the excellent safety profile, we propose their use as adjuncts in treating patients presenting COVID-19.
